RAPT Q2 2020 Earnings — RAPT Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RAPTRAPT Therapeutics, Inc.

$959M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

$1M100.0% margin

Operating Income

-$13M-979.7% margin

Net Income

-$12M-970.0% margin

EPS (Diluted)

$-4.07

QoQ Revenue Growth

+36.6%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$140M

Total Liabilities

$17M

Stockholders' Equity

$123M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	$1M	$0	—
Operating Income	-$13M	-$11M	-14.2%
Net Income	-$12M	-$11M	-16.6%